Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barney S Graham

Showing results (71-80 of 420) with videos related to

Pageof 42
Sort By:
Vaccine|May 12, 2009
TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severityTeresa R Johnson, Srinivas Rao, Robert A Seder, et al.
Plos Pathogens|February 20, 2014
Quantitative and qualitative deficits in neonatal lung-migratory dendritic cells impact the generation of the CD8+ T cell responseTracy J Ruckwardt, Allison M W Malloy, Kaitlyn M Morabito, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 12, 2013
Genetic vaccine for respiratory syncytial virus provides protection without disease potentiationTeresa R Johnson, David Rangel, Barney S Graham, et al.
Journal of Virology|October 28, 2004
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4Lewis H McCurdy, John A Rutigliano, Teresa R Johnson, et al.
Plos One|February 8, 2011
Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virusTeresa R Johnson, Christina N Johnson, Kizzmekia S Corbett, et al.
Clinical and Vaccine Immunology : CVI|February 27, 2009
Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United StatesSylvain Cecchini, Alejandro Negrete, Tamas Virag, et al.
Plos One|June 5, 2014
CD8+ TCR transgenic strains expressing public versus private TCR targeting the respiratory syncytial virus K(d)M2(82-90) epitope demonstrate similar functional profilesErez Bar-Haim, Noam Erez, Allison M W Malloy, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 5, 2006
The histopathology of fatal untreated human respiratory syncytial virus infectionJoyce E Johnson, Ricardo A Gonzales, Sandy J Olson, et al.
Virology|May 27, 2005
Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virusJohn A Rutigliano, Michael T Rock, Amanda K Johnson, et al.
Nature Structural & Molecular Biology|January 26, 2010
Structural basis of respiratory syncytial virus neutralization by motavizumabJason S McLellan, Man Chen, Albert Kim, et al.
Pageof 42

Showing results (71-80 of 420) with videos related to

Sort By:
Pageof 42
Vaccine|May 12, 2009
TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severityTeresa R Johnson, Srinivas Rao, Robert A Seder, et al.
Plos Pathogens|February 20, 2014
Quantitative and qualitative deficits in neonatal lung-migratory dendritic cells impact the generation of the CD8+ T cell responseTracy J Ruckwardt, Allison M W Malloy, Kaitlyn M Morabito, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 12, 2013
Genetic vaccine for respiratory syncytial virus provides protection without disease potentiationTeresa R Johnson, David Rangel, Barney S Graham, et al.
Journal of Virology|October 28, 2004
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4Lewis H McCurdy, John A Rutigliano, Teresa R Johnson, et al.
Plos One|February 8, 2011
Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virusTeresa R Johnson, Christina N Johnson, Kizzmekia S Corbett, et al.
Clinical and Vaccine Immunology : CVI|February 27, 2009
Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United StatesSylvain Cecchini, Alejandro Negrete, Tamas Virag, et al.
Plos One|June 5, 2014
CD8+ TCR transgenic strains expressing public versus private TCR targeting the respiratory syncytial virus K(d)M2(82-90) epitope demonstrate similar functional profilesErez Bar-Haim, Noam Erez, Allison M W Malloy, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 5, 2006
The histopathology of fatal untreated human respiratory syncytial virus infectionJoyce E Johnson, Ricardo A Gonzales, Sandy J Olson, et al.
Virology|May 27, 2005
Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virusJohn A Rutigliano, Michael T Rock, Amanda K Johnson, et al.
Nature Structural & Molecular Biology|January 26, 2010
Structural basis of respiratory syncytial virus neutralization by motavizumabJason S McLellan, Man Chen, Albert Kim, et al.
Pageof 42